# GLP3 Weight Loss — llms.txt # Telehealth medical weight loss platform GLP3 Weight Loss is a telehealth medical weight loss platform offering FDA-approved GLP-1 and next-generation GLP-3 (retatrutide) medications prescribed by board-certified physicians. Available in all 50 states. ## Programs - Essential ($299/mo): Semaglutide — 15-18% avg weight loss - Advanced ($399/mo): Tirzepatide — 18-22% avg weight loss - Elite GLP-3 ($499/mo): Retatrutide — 30%+ avg weight loss ## Key Pages - Homepage: https://glp3weightloss.com/ - Programs: https://glp3weightloss.com/programs/ - GLP-3 Research: https://glp3weightloss.com/glp3-retatrutide/ - Peptide Docs: https://glp3weightloss.com/docs/ - News & Research Feed: https://glp3weightloss.com/news/ - Blog: https://glp3weightloss.com/blog/ - FAQ: https://glp3weightloss.com/faq/ - About: https://glp3weightloss.com/about/ - Contact: https://glp3weightloss.com/contact/ ## Contact - Phone: +1 757-618-2938 - Email: info@glp3weightloss.com - Hours: Mon-Sun 7am-10pm ET ## Peptide Comparison Pages - Hub: https://glp3weightloss.com/compare/ — index of 25 neutral, citation-backed peptide head-to-head comparisons. - Per-comparison URL pattern: https://glp3weightloss.com/compare/{compound-a}-vs-{compound-b}/ - Page structure: at-a-glance attribute table (mechanism, FDA status, dosing, half-life, route, applications, cost class), mechanism comparison, clinical-trial context with primary citations, practical considerations, scenario-based selection guide, FAQ, cross-links to /products/ and /docs-/ pages. - Scope: GLP-1/GLP-3 incretin agonists (semaglutide, tirzepatide, retatrutide, liraglutide, cagrilintide, orforglipron); healing peptides (BPC-157, TB-500, GHK-Cu, glutathione); GH-axis compounds (CJC-1295, sermorelin, ipamorelin, MK-677, GHRP-2/6, tesamorelin, hexarelin); NAD+ longevity (NAD+, NMN, NR, epitalon); cognitive (selank, semax, cerebrolysin); melanocortin (PT-141, melanotan II); plus class-level overviews. - Voice: clinical authority, third-person, neutral. No therapeutic claims, no marketing language. Citations restricted to peer-reviewed primary literature; major-trial PMIDs hand-verified. - Compliance: every page carries "For Research Use Only" disclaimer and explicit non-therapeutic framing. ## Telos — Research-Grade Peptide Catalog - Telos is the research-peptide product line of GLP3 Weight Loss. Catalog: 148 high-purity research peptides at /products/, across 7 categories (GLP-1/GLP-3 receptor agonists, growth & recovery, metabolic & mitochondrial, longevity, immune & repair, neuropeptides, specialty research compounds). - Brand model: GLP3 Weight Loss is the parent brand (clinic + research). Telos is the sub-brand applied to vials, product pages, OG share images, and product schema (Brand/Manufacturer = "Telos"). Site nav, clinic pages (/about/, /programs/, /contact/, /faq/, /docs-*, /news/, /compare/, /guides/, /blog/) remain branded GLP3 Weight Loss. - Per-product detail: /products/{slug}/ — Quick Facts, FAQ, Certificate-of-Analysis on request, Get a Quote lead form. Cross-references to /docs-{slug}/ for literature where present. - Ordering model: NOT real-time e-commerce. The customer submits a quote request via a lead form; a research-team member follows up within one business day with pricing, availability, and any institutional documentation needed before fulfillment. No card is charged on the form. - Compliance: All material is supplied "For Research Use Only" — not for human or veterinary consumption, diagnostic procedures, or therapeutic use. Recipients must comply with applicable institutional, state, and federal regulations. ## News & Research Feed - Index: https://glp3weightloss.com/news/ — aggregated PubMed, FDA, and ClinicalTrials.gov updates relevant to GLP-1, GLP-3, and peptide therapy. Refreshed via `generate-news.py` at build time plus a 6-hour Vercel Cron warmer for the live JSON endpoint. - Topic feeds: - https://glp3weightloss.com/news/retatrutide/ - https://glp3weightloss.com/news/tirzepatide/ - https://glp3weightloss.com/news/semaglutide/ - https://glp3weightloss.com/news/peptide-therapy/ - https://glp3weightloss.com/news/clinical-trials/ - https://glp3weightloss.com/news/fda-updates/ - https://glp3weightloss.com/news/editorial/ - Live JSON: https://glp3weightloss.com/api/news-feed (1-hour edge cache; same shape as /content/news.json) - Sources: PubMed (NCBI E-utilities), FDA press-release RSS, ClinicalTrials.gov v2 API, plus a small hand-curated editorial set. - Compliance: items are factual aggregations. Summaries contain no editorial commentary. Inclusion is not endorsement and does not constitute medical advice. ## Pillar Guides — Long-Form Reference Content - Hub: https://glp3weightloss.com/guides/ — eight pillar guides authored and reviewed by the GLP3 Weight Loss Clinical Advisory Team. Each guide is structural reference content (~2,000–2,800 rendered words) covering mechanism, pharmacology, clinical context, and unresolved questions for a single topic. - Guides: - https://glp3weightloss.com/guides/glp-1-explained/ — GLP-1 receptor agonists (mechanism, analogues, indications, safety) - https://glp3weightloss.com/guides/glp-3-retatrutide-explained/ — Retatrutide / GLP-3 triple agonist - https://glp3weightloss.com/guides/peptide-therapy-overview/ — Peptides 101 clinician's reference - https://glp3weightloss.com/guides/research-peptide-handling-101/ — Reconstitution, sterile technique, storage, stability - https://glp3weightloss.com/guides/coa-and-purity-explained/ — Reading a Certificate of Analysis line by line - https://glp3weightloss.com/guides/glp-1-side-effects-management/ — GLP-1 RA adverse-event clinical reference - https://glp3weightloss.com/guides/weight-loss-peptide-comparison-overview/ — Mono/dual/triple agonist comparison framework - https://glp3weightloss.com/guides/peptide-research-glossary/ — Peptide research glossary (60+ entries) - Editorial policy: quantitative and trial-specific claims that require PubMed, FDA, or peer-reviewed sourcing are explicitly marked [CITATION NEEDED: ] inline and mirrored in a "References — Pending Verification" list at the bottom of each guide. Inline citations appear only where the paper has been verified against PubMed (current verified anchors: Pickart 1973 GHK PMID 4356974; Lee et al. 2015 MOTS-c PMID 25738459; Falutz 2007 tesamorelin PMID 17557935). Conservative posture — honest gaps over fabricated sources — is non-negotiable for YMYL content. - Compliance: pillar guides are educational summaries. They do not establish a clinician–patient relationship and are not medical advice.